[
  {
    "ts": null,
    "headline": "69 July Aristocrats: Hormel Is Still The One Hot Dog",
    "summary": "69 July Aristocrats: Hormel Is Still The One Hot Dog",
    "url": "https://finnhub.io/api/news?id=9d5f9ffd24dedbfd1cc6eaaf91969ec84bb3c12c732fdb22fe304a25b5d09097",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753295529,
      "headline": "69 July Aristocrats: Hormel Is Still The One Hot Dog",
      "id": 136060294,
      "image": "",
      "related": "ABBV",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=9d5f9ffd24dedbfd1cc6eaaf91969ec84bb3c12c732fdb22fe304a25b5d09097"
    }
  },
  {
    "ts": null,
    "headline": "A Major Market Rotation Is Likely Coming",
    "summary": "A major market disruption may be imminent despite AI-driven highs. Read about which stocks I recommend investing in instead.",
    "url": "https://finnhub.io/api/news?id=b7febad88bada0d483bc4faaa0721d91be81cdc22f1a853559c9466a29b0c55d",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753294271,
      "headline": "A Major Market Rotation Is Likely Coming",
      "id": 136060191,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2039568842/image_2039568842.jpg?io=getty-c-w1536",
      "related": "ABBV",
      "source": "SeekingAlpha",
      "summary": "A major market disruption may be imminent despite AI-driven highs. Read about which stocks I recommend investing in instead.",
      "url": "https://finnhub.io/api/news?id=b7febad88bada0d483bc4faaa0721d91be81cdc22f1a853559c9466a29b0c55d"
    }
  },
  {
    "ts": null,
    "headline": "Rheumatologists Eye AbbVie’s Rinvoq, Roche/Genentech’s Gazyva, and Bristol Myers Squibb’s Sotyktu as Front-Runners to Address Persistent Gaps in Systemic Lupus Erythematosus Care, Spherix Global Insights Reports",
    "summary": "Rheumatologists expect new mechanisms of action to reshape the SLE landscape as demand grows for safer, more effective options—particularly therapies with steroid-sparing potential and easier administrationEXTON, PA, July 23, 2025 (GLOBE NEWSWIRE) -- Biologic use in systemic lupus erythematosus (SLE) is steadily rising, with U.S. rheumatologists now treating close to 40% of their moderate-to-severe patients with biologics. Most expect this number to increase as comfort with existing therapies gr",
    "url": "https://finnhub.io/api/news?id=0e6d970d13d47cefca8639dfa2432d03bea544cea597ffa32273ff6b25805048",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753289460,
      "headline": "Rheumatologists Eye AbbVie’s Rinvoq, Roche/Genentech’s Gazyva, and Bristol Myers Squibb’s Sotyktu as Front-Runners to Address Persistent Gaps in Systemic Lupus Erythematosus Care, Spherix Global Insights Reports",
      "id": 136062151,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Rheumatologists expect new mechanisms of action to reshape the SLE landscape as demand grows for safer, more effective options—particularly therapies with steroid-sparing potential and easier administrationEXTON, PA, July 23, 2025 (GLOBE NEWSWIRE) -- Biologic use in systemic lupus erythematosus (SLE) is steadily rising, with U.S. rheumatologists now treating close to 40% of their moderate-to-severe patients with biologics. Most expect this number to increase as comfort with existing therapies gr",
      "url": "https://finnhub.io/api/news?id=0e6d970d13d47cefca8639dfa2432d03bea544cea597ffa32273ff6b25805048"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie Inc. stock outperforms competitors on strong trading day",
    "summary": "AbbVie Inc. stock outperforms competitors on strong trading day",
    "url": "https://finnhub.io/api/news?id=028282bf7ce318475651ceccd900f95b90289a78815f12f4ea0ccfdc35a34cc9",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753288320,
      "headline": "AbbVie Inc. stock outperforms competitors on strong trading day",
      "id": 136069451,
      "image": "",
      "related": "ABBV",
      "source": "MarketWatch",
      "summary": "AbbVie Inc. stock outperforms competitors on strong trading day",
      "url": "https://finnhub.io/api/news?id=028282bf7ce318475651ceccd900f95b90289a78815f12f4ea0ccfdc35a34cc9"
    }
  },
  {
    "ts": null,
    "headline": "Accelerating innovation in early Alzheimer’s disease diagnosis",
    "summary": "Roche is focusing on early diagnosis of Alzheimer's disease and will soon release its first blood-based biomarker for the disease.",
    "url": "https://finnhub.io/api/news?id=dd09738e8944ae73653699a4082087e484729880fafb7983963f87c4a08ad58d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753288226,
      "headline": "Accelerating innovation in early Alzheimer’s disease diagnosis",
      "id": 136088569,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Roche is focusing on early diagnosis of Alzheimer's disease and will soon release its first blood-based biomarker for the disease.",
      "url": "https://finnhub.io/api/news?id=dd09738e8944ae73653699a4082087e484729880fafb7983963f87c4a08ad58d"
    }
  },
  {
    "ts": null,
    "headline": "QDEF: Dividend ETF With Little To Show",
    "summary": "FlexShares Quality Dividend Defensive Index Fund ETF has a portfolio of 127 dividend stocks based on a quality score and beta optimization. Read why QDEF is a Buy.",
    "url": "https://finnhub.io/api/news?id=6a3a4e23ad540f3dfa7c83a99e1e86bf5e8074bc3d76e82a0ae0d0aff4ac124a",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753281748,
      "headline": "QDEF: Dividend ETF With Little To Show",
      "id": 136049720,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1389129618/image_1389129618.jpg?io=getty-c-w1536",
      "related": "ABBV",
      "source": "SeekingAlpha",
      "summary": "FlexShares Quality Dividend Defensive Index Fund ETF has a portfolio of 127 dividend stocks based on a quality score and beta optimization. Read why QDEF is a Buy.",
      "url": "https://finnhub.io/api/news?id=6a3a4e23ad540f3dfa7c83a99e1e86bf5e8074bc3d76e82a0ae0d0aff4ac124a"
    }
  },
  {
    "ts": null,
    "headline": "Atopic Dermatitis Market Forecast Report 2025-2034 | FDA Approval of Tralokinumab-Ldrm Stimulates Treatment Advances",
    "summary": "The atopic dermatitis market, valued at USD 9.33 billion in 2024, is projected to grow at a CAGR of 15.10%, reaching USD 38.07 billion by 2034. Key drivers include increasing prevalence, FDA approvals like LEO Pharma's tralokinumab-ldrm, and novel treatments. Major players include AbbVie, Pfizer, and Regeneron. Atopic Dermatitis Market Atopic Dermatitis Market Dublin, July 23, 2025 (GLOBE NEWSWIRE) -- The \"Atopic Dermatitis Market Report and Forecast 2025-2034\" report has been added to ResearchA",
    "url": "https://finnhub.io/api/news?id=9bf7f683fd614ffa47b5eb4949231acd9dc19d386149783b004bef4232492def",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753258080,
      "headline": "Atopic Dermatitis Market Forecast Report 2025-2034 | FDA Approval of Tralokinumab-Ldrm Stimulates Treatment Advances",
      "id": 136039632,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "The atopic dermatitis market, valued at USD 9.33 billion in 2024, is projected to grow at a CAGR of 15.10%, reaching USD 38.07 billion by 2034. Key drivers include increasing prevalence, FDA approvals like LEO Pharma's tralokinumab-ldrm, and novel treatments. Major players include AbbVie, Pfizer, and Regeneron. Atopic Dermatitis Market Atopic Dermatitis Market Dublin, July 23, 2025 (GLOBE NEWSWIRE) -- The \"Atopic Dermatitis Market Report and Forecast 2025-2034\" report has been added to ResearchA",
      "url": "https://finnhub.io/api/news?id=9bf7f683fd614ffa47b5eb4949231acd9dc19d386149783b004bef4232492def"
    }
  }
]